Request Demo

Last update 08 May 2025

Acetaminophen/Butalbital

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

COXs x GABAA receptor

Action

inhibitors, agonists

Mechanism

COX inhibitors(Cyclooxygenases inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Tension-Type Headache

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC11H16N2O3

InChIKeyUZVHFVZFNXBMQJ-UHFFFAOYSA-N

CAS Registry77-26-9

View All Structures (2)

100 Clinical Results associated with Acetaminophen/Butalbital

100 Translational Medicine associated with Acetaminophen/Butalbital

100 Patents (Medical) associated with Acetaminophen/Butalbital

Literatures (Medical) associated with Acetaminophen/Butalbital

01 Jan 2000·Acta HaematologicaQ4 · MEDICINE

A Pilot Study of Busulfan, Cyclophosphamide and Etoposide Followed by Autologous Transplantation for Acute Myeloid Leukemia in Remission

Q4 · MEDICINE

Article

Author: Clive, J. ; Kazierad, D. ; Bona, R. D. ; Furlong, F. ; Tutschka, P. J. ; Naqvi, B. H. ; Edwards, R. L. ; Bilgrami, S. ; Fox, J.

Patients with acute myeloid leukemia (AML) have experienced an improvement in outcome with current intensification regimens.However, some subsets of patients may have an increased likelihood of relapse.We report the preliminary results of a pilot study utilizing busulfan, cyclophosphamide and etoposide (BuCEt) followed by autologous hematopoietic stem cell transplantation (HSCT) in patients with AML in first or greater complete remission.Adults aged 15 yr or older with AML in CR1 or greater who did not have a suitable donor were eligible for this study.The source of hematopoietic stem cells (HSC) was either the bone marrow or the peripheral blood.Bone marrow was harvested from the posterior iliac crests under general anesthesia.Peripheral blood stems cells (PBSC) were harvested after a mobilization regimen of etoposide 60 mg/kg ideal body weight i.v. (hour 0-18), cyclophosphamide 3 g/m2 i.v. in two divided doses (hour 24-25 and 30-31), paclitaxel 200 mg/ m2 i.v. (hour 48-51) (TEC), and granulocyte colony-stimulating factor (G-CSF) 5 gg/kg/day i.v. from hour 60 until recovery of the absolute neutrophil count (ANC >1 x 109/1) and collection of the PBSC.The conditioning regimen consisted of busulfan 1 mg/kg/day p.o., administered 4 times each day for 4 days (days -7, -6, -5 and -4), etoposide 60 mg/kg ideal body weight i.v. over 18 h on day -3, and cyclophosphamide 45 mg/kg i.v. over 1 h times two doses administered 6 h apart on day -2 (BuCEt).We utilized a combination of TEC along with G-CSF to mobilize and harvest PBSC.This regimen was successful especially among patients with AML in CR1, likely because these individuals had received less prior chemotherapy.The transplantation regimen administered in this study was tolerated well and was associated with few adverse effects, and only one heavily pretreated patient died from sepsis in the early posttransplantation period.Patients who underwent an autologous bone marrow transplantation after a failed attempt at PBSC mobilization had a prolonged period of transfusion dependency.The results of this pilot trial suggest that BuCEt is easy to administer and well tolerated.Together with autologous HSCT, it can produce long-term LFS in 49% of patients at standard or high risk for relapse.Further study is warranted.

100 Deals associated with Acetaminophen/Butalbital

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N02BE71	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Tension-Type Headache	United States	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis